Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365519904> ?p ?o ?g. }
- W4365519904 endingPage "e703" @default.
- W4365519904 startingPage "e693" @default.
- W4365519904 abstract "Drug-sensitive tuberculosis treatment requires 6 months of therapy, so adherence problems are common. Digital adherence technologies might improve tuberculosis treatment outcomes. We aimed to evaluate the effect of a daily reminder medication monitor, monthly review of adherence data by the health-care provider, and differentiated care for patients with adherence issues, on tuberculosis treatment adherence and outcomes.We did a cluster-randomised superiority trial across four prefectures in China. 24 counties or districts (clusters) were randomly assigned (1:1) to intervention or control groups. We enrolled patients aged 18 years or older with GeneXpert-positive, rifampicin-sensitive pulmonary tuberculosis, who were receiving daily fixed-dose combination treatment. Patients in the intervention group received a medication monitor for daily drug-dosing reminders, monthly review of adherence data by health-care provider, and management of poor adherence; and patients in the control group received routine care (silent-mode monitor-measured adherence). Only the independent endpoints review committee who assessed endpoint data for some participants were masked to study group assignment. Patients were followed up (with sputum solid culture) at 12 and 18 months. The primary outcome was a composite of death, loss to follow-up, treatment failure, switch to multidrug-resistant tuberculosis treatment, or tuberculosis recurrence by 18 months from treatment start, analysed in the intention-to-treat population. Analysis accounted for study design with multiple imputation for the primary outcome. This trial is now complete and is registered with ISRCTN, 35812455.Between Jan 26, 2017, and April 3, 2019, 15 257 patients were assessed for eligibility and 3074 were enrolled, 2686 (87%) of whom were included in the intention-to-treat population. 1909 (71%) of 2686 patients were male, 777 (29%) were female, and the median age was 44 years (IQR 29-58). By 18 months from treatment start, using multiple imputation for missing outcomes, 239 (16% [geometric mean of cluster-level proportion]) of 1388 patients in the control group and 224 (16%) of 1298 in the intervention group had a primary composite outcome event (289 [62%] of 463 events were loss to follow-up during treatment and 42 [9%] were tuberculosis recurrence). The intervention had no effect on risk of the primary composite outcome (adjusted risk ratio 1·01, 95% CI 0·73-1·40).Our digital medication monitor intervention had no effect on unfavourable outcomes, which included loss to follow-up during treatment, tuberculosis recurrence, death, and treatment failure. There was a failure to change patient management following identification of treatment non-adherence at monthly reviews. A better understanding of adherence patterns and how they relate to poor outcomes, coupled with a more timely review of adherence data and improved implementation of differentiated care, may be required.Bill & Melinda Gates Foundation." @default.
- W4365519904 created "2023-04-15" @default.
- W4365519904 creator A5003759585 @default.
- W4365519904 creator A5011782450 @default.
- W4365519904 creator A5013524550 @default.
- W4365519904 creator A5022288989 @default.
- W4365519904 creator A5025741583 @default.
- W4365519904 creator A5026823919 @default.
- W4365519904 creator A5030465244 @default.
- W4365519904 creator A5033684035 @default.
- W4365519904 creator A5042465445 @default.
- W4365519904 creator A5045367888 @default.
- W4365519904 creator A5045452010 @default.
- W4365519904 creator A5046691137 @default.
- W4365519904 creator A5052893081 @default.
- W4365519904 creator A5056878177 @default.
- W4365519904 creator A5065590805 @default.
- W4365519904 creator A5076681738 @default.
- W4365519904 creator A5077196269 @default.
- W4365519904 date "2023-05-01" @default.
- W4365519904 modified "2023-09-26" @default.
- W4365519904 title "Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial" @default.
- W4365519904 cites W1224136941 @default.
- W4365519904 cites W1925415092 @default.
- W4365519904 cites W2060886162 @default.
- W4365519904 cites W2114394851 @default.
- W4365519904 cites W2134843796 @default.
- W4365519904 cites W2337619826 @default.
- W4365519904 cites W2346255608 @default.
- W4365519904 cites W2810683857 @default.
- W4365519904 cites W2884488266 @default.
- W4365519904 cites W2895784427 @default.
- W4365519904 cites W2917873407 @default.
- W4365519904 cites W2993596035 @default.
- W4365519904 cites W2994185183 @default.
- W4365519904 cites W3086355866 @default.
- W4365519904 cites W3136167749 @default.
- W4365519904 cites W3157487954 @default.
- W4365519904 cites W3159002700 @default.
- W4365519904 cites W4205885574 @default.
- W4365519904 cites W4206725418 @default.
- W4365519904 cites W4210609564 @default.
- W4365519904 doi "https://doi.org/10.1016/s2214-109x(23)00068-2" @default.
- W4365519904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37061308" @default.
- W4365519904 hasPublicationYear "2023" @default.
- W4365519904 type Work @default.
- W4365519904 citedByCount "2" @default.
- W4365519904 countsByYear W43655199042023 @default.
- W4365519904 crossrefType "journal-article" @default.
- W4365519904 hasAuthorship W4365519904A5003759585 @default.
- W4365519904 hasAuthorship W4365519904A5011782450 @default.
- W4365519904 hasAuthorship W4365519904A5013524550 @default.
- W4365519904 hasAuthorship W4365519904A5022288989 @default.
- W4365519904 hasAuthorship W4365519904A5025741583 @default.
- W4365519904 hasAuthorship W4365519904A5026823919 @default.
- W4365519904 hasAuthorship W4365519904A5030465244 @default.
- W4365519904 hasAuthorship W4365519904A5033684035 @default.
- W4365519904 hasAuthorship W4365519904A5042465445 @default.
- W4365519904 hasAuthorship W4365519904A5045367888 @default.
- W4365519904 hasAuthorship W4365519904A5045452010 @default.
- W4365519904 hasAuthorship W4365519904A5046691137 @default.
- W4365519904 hasAuthorship W4365519904A5052893081 @default.
- W4365519904 hasAuthorship W4365519904A5056878177 @default.
- W4365519904 hasAuthorship W4365519904A5065590805 @default.
- W4365519904 hasAuthorship W4365519904A5076681738 @default.
- W4365519904 hasAuthorship W4365519904A5077196269 @default.
- W4365519904 hasBestOaLocation W43655199041 @default.
- W4365519904 hasConcept C126322002 @default.
- W4365519904 hasConcept C142724271 @default.
- W4365519904 hasConcept C168563851 @default.
- W4365519904 hasConcept C1862650 @default.
- W4365519904 hasConcept C2776301714 @default.
- W4365519904 hasConcept C2779912665 @default.
- W4365519904 hasConcept C2781069245 @default.
- W4365519904 hasConcept C2908647359 @default.
- W4365519904 hasConcept C2909923361 @default.
- W4365519904 hasConcept C71924100 @default.
- W4365519904 hasConcept C99454951 @default.
- W4365519904 hasConceptScore W4365519904C126322002 @default.
- W4365519904 hasConceptScore W4365519904C142724271 @default.
- W4365519904 hasConceptScore W4365519904C168563851 @default.
- W4365519904 hasConceptScore W4365519904C1862650 @default.
- W4365519904 hasConceptScore W4365519904C2776301714 @default.
- W4365519904 hasConceptScore W4365519904C2779912665 @default.
- W4365519904 hasConceptScore W4365519904C2781069245 @default.
- W4365519904 hasConceptScore W4365519904C2908647359 @default.
- W4365519904 hasConceptScore W4365519904C2909923361 @default.
- W4365519904 hasConceptScore W4365519904C71924100 @default.
- W4365519904 hasConceptScore W4365519904C99454951 @default.
- W4365519904 hasIssue "5" @default.
- W4365519904 hasLocation W43655199041 @default.
- W4365519904 hasLocation W43655199042 @default.
- W4365519904 hasLocation W43655199043 @default.
- W4365519904 hasOpenAccess W4365519904 @default.
- W4365519904 hasPrimaryLocation W43655199041 @default.
- W4365519904 hasRelatedWork W114868831 @default.
- W4365519904 hasRelatedWork W1980740705 @default.
- W4365519904 hasRelatedWork W1987247410 @default.